The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Unharmonious ivonescimab reveal for Summit
The same trial that sent Summit up 272% sees the stock crash 36%.
AACR 2025 – Merck's head and neck headscratcher
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
AUA 2025 – Pfizer catches the Crest of a subQ wave
But sasanlimab's use looks set to remain narrow.
